COMPANY PIPELINE

VACCINE PROGRAMS CURRENTLY UNDER DEVELOPMENT

CDIFFVAC: A superior broad-protective toxoid vaccine for treatment of recurrent Clostridium difficile infection 

PTVAC: A more immunogenic and longer-lasting nasal vaccine for prevention of whooping cough

UTIVAC: A multi-faceted nasal vaccine for prevention and treatment of urinary tract infection caused by UPEC 

CLOSTRIDIUM DIFFICILE INFECTION (CDI)

A significant unmet medical need

  • C. difficile is the leading cause of healthcare-associated infectious diarrhea
  • Disease symptoms caused by two toxins


  • CDI is mainly caused by antibiotic use
  • Patients >65 years are at higher risk
  • Recurrent infections in ca. 25% of patients

  • Emerging AMR in C. difficile is a significant threat to global healthcare systems


  • > 800.000 infections (annually)
  • > 60.000 deaths (annually)



  • AMR Hazard level "Urgent Threats" (CDC)

CDI is associated with significant economic burden

5.9 billion EUR

in annual costs in the US due to CDI

    2.8 billion EUR

    in annual costs in the European Union due to CDI

      CDI causes a wide spectrum of disease symptoms that are often debilitating


      WHOOPING COUGH

      Resurging due to waning vaccine protection

      • Whooping cough is a contagious respiratory tract infection caused by Bordetella pertussis
      • Symptoms are mainly due to the secreted pertussis toxin


      • Current vaccines show waning effectiveness a few years after booster shots leading to serious outbreaks



      • > 24 million infections
      • > 160.000 deaths



        • Macrolide-resistant B. pertussis is on CDC's AMR "Watch List"

        URINARY TRACT INFECTION (UTI)

        One of the most common infections worldwide

        • Disease mainly caused by uropathogenic E. coli (UPEC) - ca. 80-90% of UTIs
          • Secretes two toxins that cause severe tissue damage


        • Extensive use of antibiotic has caused a huge emerging AMR problem
          • 10-20% of UPEC strains are multi drug resistant
        • Recurrent infections in ca. 1 out of 3


        • > 400 million infections
        • > 236.000 deaths


        • 60% of women have ≥ 1 UTI per lifetime
        • 11% of women have ≥ 1 UTI per year

        FOLLOW OUR PROJECTS

        Copyright 2023 Proxi Biotech ApS All Rights Reserved